These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35475258)

  • 21. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
    Kumar D; Ison MG; Mira JP; Welte T; Hwan Ha J; Hui DS; Zhong N; Saito T; Katugampola L; Collinson N; Williams S; Wildum S; Ackrill A; Clinch B; Lee N
    Lancet Infect Dis; 2022 May; 22(5):718-730. PubMed ID: 35085510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
    Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
    Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Villiger PM; Adler S; Kuchen S; Wermelinger F; Dan D; Fiege V; Bütikofer L; Seitz M; Reichenbach S
    Lancet; 2016 May; 387(10031):1921-7. PubMed ID: 26952547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
    Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity: A structured summary of a study protocol for a randomised controlled trial.
    Rangnekar H; Patankar S; Suryawanshi K; Soni P
    Trials; 2020 Nov; 21(1):943. PubMed ID: 33225970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Masuda T; Murakami K; Sugiura K; Sakui S; Philip Schuring R; Mori M
    Vaccine; 2022 Mar; 40(13):2044-2052. PubMed ID: 35177302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocilizumab in severe COVID-19 - A randomized, double-blind, placebo-controlled trial.
    Malik MI; Zafar SAF; Qayyum F; Malik M; Asghar MS; Tahir MJ; Arshad A; Khalil F; Naz HS; Aslam M; Saleem J; Aziz A; Azhar MU; Naqash M; Yousaf Z
    Infect Med (Beijing); 2022 Jun; 1(2):88-94. PubMed ID: 38013720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
    Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
    Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis.
    Fiorentino G; Coppola A; Izzo R; Annunziata A; Bernardo M; Lombardi A; Trimarco V; Santulli G; Trimarco B
    EClinicalMedicine; 2021 Oct; 40():101125. PubMed ID: 34522871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trial.
    Sager P; Kaiser A; Schumann S; Ludescher B; Niedermaier M; Schmidt I; Och K; Dings C; Lehr T; Brysch W
    Lancet Reg Health Eur; 2024 Feb; 37():100810. PubMed ID: 38076629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial.
    Salvarani C; Massari M; Costantini M; Merlo DF; Mariani GL; Viale P; Nava S; Guaraldi G; Dolci G; Boni L; Savoldi L; Bruzzi P; Turrà C; Catanoso M; Marata AM; Barbieri C; Valcavi A; Franzoni F; Cavuto S; Mazzi G; Corsini R; Trapani F; Bartoloni A; Barisione E; Barbieri C; Burastero GJ; Pan A; Inojosa W; Scala R; Burattini C; Luppi F; Codeluppi M; Tarek KE; Cenderello G; Salio M; Foti G; Dongilli R; Bajocchi G; Negri EA; Ciusa G; Fornaro G; Bassi I; Zammarchi L; Aloè T; Facciolongo N
    Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35361632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous Tocilizumab versus Standard of Care in the Treatment of Severe and Critical COVID-19-related Pneumonia: A Single-center, Double-blind, Placebo-controlled, Phase 3 Trial.
    Amante EJB; David-Wang AS; Tee ML; Punzalan FER; Añonuevo JC; Fernandez LC; Albay AB; Malabad JCM; Climacosa FMM; Pajes ANNI; Cuaño PMGM; Alejandría MM
    Acta Med Philipp; 2024; 58(6):7-13. PubMed ID: 38846161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of Coronavirus Disease 2019.
    Bramante CT; Beckman KB; Mehta T; Karger AB; Odde DJ; Tignanelli CJ; Buse JB; Johnson DM; Watson RHB; Daniel JJ; Liebovitz DM; Nicklas JM; Cohen K; Puskarich MA; Belani HK; Siegel LK; Klatt NR; Anderson B; Hartman KM; Rao V; Hagen AA; Patel B; Fenno SL; Avula N; Reddy NV; Erickson SM; Fricton RD; Lee S; Griffiths G; Pullen MF; Thompson JL; Sherwood NE; Murray TA; Rose MR; Boulware DR; Huling JD;
    Clin Infect Dis; 2024 May; ():. PubMed ID: 38690892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort study.
    Sava M; Sommer G; Daikeler T; Woischnig AK; Martinez AE; Leuzinger K; Hirsch HH; Erlanger T; Wiencierz A; Bassetti S; Tamm M; Tschudin-Sutter S; Stoeckle M; Pargger H; Siegemund M; Boss R; Zimmer G; Vu DL; Kaiser L; Dell-Kuster S; Weisser M; Battegay M; Hostettler K; Khanna N
    Swiss Med Wkly; 2021 Aug; 151():w20550. PubMed ID: 34375986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial.
    Kumar PN; Hernández-Sánchez J; Nagel S; Feng Y; Cai F; Rabin J; Morse CG; Nadig NR; Ashraf O; Gotur DB; McComsey GA; Gafoor K; Perin P; Thornton SC; Stubbings W; Lin CJF; Tsai L
    Open Forum Infect Dis; 2022 Jan; 9(1):ofab608. PubMed ID: 35024375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19.
    Shivram H; Hackney JA; Rosenberger CM; Teterina A; Qamra A; Onabajo O; McBride J; Cai F; Bao M; Tsai L; Regev A; Rosas IO; Bauer RN
    iScience; 2023 Sep; 26(9):107597. PubMed ID: 37664617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.